Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review

The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimatsu, Yuki, Ebi, Noriyuki, Ooi, Ryunosuke, Sueyasu, Takuto, Nishizawa, Saori, Munechika, Miyuki, Yoshimine, Kohei, Ko, Yuki, Ide, Hiromi, Tsuruno, Kosuke, Tobino, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079920/
https://www.ncbi.nlm.nih.gov/pubmed/33132329
http://dx.doi.org/10.2169/internalmedicine.5463-20
_version_ 1783685319336394752
author Yoshimatsu, Yuki
Ebi, Noriyuki
Ooi, Ryunosuke
Sueyasu, Takuto
Nishizawa, Saori
Munechika, Miyuki
Yoshimine, Kohei
Ko, Yuki
Ide, Hiromi
Tsuruno, Kosuke
Tobino, Kazunori
author_facet Yoshimatsu, Yuki
Ebi, Noriyuki
Ooi, Ryunosuke
Sueyasu, Takuto
Nishizawa, Saori
Munechika, Miyuki
Yoshimine, Kohei
Ko, Yuki
Ide, Hiromi
Tsuruno, Kosuke
Tobino, Kazunori
author_sort Yoshimatsu, Yuki
collection PubMed
description The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib was resumed after sixth-line chemotherapy was ineffective, showing efficacy again. Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. This is the first report to show its effect in a case of rechallenge after intervening chemotherapy. It may therefore be important to evaluate EGFR in never-smoker lung squamous cell carcinoma patients.
format Online
Article
Text
id pubmed-8079920
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-80799202021-05-11 Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review Yoshimatsu, Yuki Ebi, Noriyuki Ooi, Ryunosuke Sueyasu, Takuto Nishizawa, Saori Munechika, Miyuki Yoshimine, Kohei Ko, Yuki Ide, Hiromi Tsuruno, Kosuke Tobino, Kazunori Intern Med Case Report The efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung squamous cell carcinoma is said to be low. Thus far, only four cases of osimertinib in lung squamous cell carcinoma have been published. We experienced a case of EGFR mutant lung squamous cell carcinoma in which fifth-line treatment with osimertinib was effective after T790M EGFR mutation turned positive. Osimertinib was resumed after sixth-line chemotherapy was ineffective, showing efficacy again. Osimertinib may be a promising treatment option for EGFR mutant lung squamous cell carcinoma. This is the first report to show its effect in a case of rechallenge after intervening chemotherapy. It may therefore be important to evaluate EGFR in never-smoker lung squamous cell carcinoma patients. The Japanese Society of Internal Medicine 2020-11-02 2021-04-01 /pmc/articles/PMC8079920/ /pubmed/33132329 http://dx.doi.org/10.2169/internalmedicine.5463-20 Text en Copyright © 2021 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Yoshimatsu, Yuki
Ebi, Noriyuki
Ooi, Ryunosuke
Sueyasu, Takuto
Nishizawa, Saori
Munechika, Miyuki
Yoshimine, Kohei
Ko, Yuki
Ide, Hiromi
Tsuruno, Kosuke
Tobino, Kazunori
Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review
title Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review
title_full Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review
title_fullStr Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review
title_full_unstemmed Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review
title_short Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review
title_sort osimertinib for lung squamous cell carcinoma: a case report and literature review
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079920/
https://www.ncbi.nlm.nih.gov/pubmed/33132329
http://dx.doi.org/10.2169/internalmedicine.5463-20
work_keys_str_mv AT yoshimatsuyuki osimertinibforlungsquamouscellcarcinomaacasereportandliteraturereview
AT ebinoriyuki osimertinibforlungsquamouscellcarcinomaacasereportandliteraturereview
AT ooiryunosuke osimertinibforlungsquamouscellcarcinomaacasereportandliteraturereview
AT sueyasutakuto osimertinibforlungsquamouscellcarcinomaacasereportandliteraturereview
AT nishizawasaori osimertinibforlungsquamouscellcarcinomaacasereportandliteraturereview
AT munechikamiyuki osimertinibforlungsquamouscellcarcinomaacasereportandliteraturereview
AT yoshiminekohei osimertinibforlungsquamouscellcarcinomaacasereportandliteraturereview
AT koyuki osimertinibforlungsquamouscellcarcinomaacasereportandliteraturereview
AT idehiromi osimertinibforlungsquamouscellcarcinomaacasereportandliteraturereview
AT tsurunokosuke osimertinibforlungsquamouscellcarcinomaacasereportandliteraturereview
AT tobinokazunori osimertinibforlungsquamouscellcarcinomaacasereportandliteraturereview

Ejemplares similares